T. Rowe Price Associates
MLTX icon

T. Rowe Price Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History

T. Rowe Price Associates’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1M Buy
1,294,861
+335,308
+35% +$5.55M ﹤0.01% 994
2025
Q4 		$12.6M Buy
959,553
+136,596
+17% +$1.61M ﹤0.01% 1181
2025
Q3 		$5.9M Sell
822,957
-1,790,276
-69% -$93.3M ﹤0.01% 1351
2025
Q2 		$123M Sell
2,613,233
-360,597
-12% -$14.7M 0.01% 529
2025
Q1 		$116M Sell
2,973,830
-369,813
-11% -$15.9M 0.01% 525
2024
Q4 		$181M Buy
3,343,643
+363,394
+12% +$18.6M 0.02% 451
2024
Q3 		$150M Buy
2,980,249
+418,737
+16% +$19.6M 0.02% 491
2024
Q2 		$113M Buy
2,561,512
+425,629
+20% +$18M 0.01% 525
2024
Q1 		$107M Sell
2,135,883
-178,129
-8% -$9.66M 0.01% 534
2023
Q4 		$140M Buy
2,314,012
+196,144
+9% +$10.1M 0.02% 485
2023
Q3 		$121M Buy
2,117,868
+174,812
+9% +$9.65M 0.02% 480
2023
Q2 		$99.1M Buy
1,943,056
+1,112,150
+134% +$29.9M 0.01% 528
2023
Q1 		$17.8M Buy
830,906
+8,305
+1% +$140K ﹤0.01% 945
2022
Q4 		$8.64M Sell
822,601
-46,787
-5% -$416K ﹤0.01% 1080
2022
Q3 		$6.92M Sell
869,388
-1,136
-0.1% -$8.03K ﹤0.01% 1140
2022
Q2 		$4.44M Buy
870,524
+304,333
+54% +$1.91M ﹤0.01% 1437
2022
Q1 		$6.29M Sell
566,191
-180,671
-24% -$1.8M ﹤0.01% 1428
2021
Q4 		$7.39M Sell
746,862
-9,441
-1% -$93.8K ﹤0.01% 1453
2021
Q3 		$7.46M Hold
756,303
– – ﹤0.01% 1462
2021
Q2 		$7.81M Sell
756,303
-35,982
-5% -$365K ﹤0.01% 1447
2021
Q1 		$8.11M Buy
792,285
+4,500
+0.6% +$49.6K ﹤0.01% 1422
2020
Q4 		$8.53M Buy
+787,785
New +$8.36M ﹤0.01% 1366

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's MLTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its MoonLake Immunotherapeutics (MLTX) stake by 35% in Q1 2026, buying an estimated $5.55M and bringing the position to 1,294,861 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #994.

T. Rowe Price Associates first reported a position in MLTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $181M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • T. Rowe Price Associates held 1,294,861 shares of MoonLake Immunotherapeutics worth $24.1M as of Q1 2026.
  • T. Rowe Price Associates bought 335,308 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $5.55M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #994 holding.
  • T. Rowe Price Associates first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 22 quarters since.
  • T. Rowe Price Associates's MoonLake Immunotherapeutics position peaked at $181M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.